Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX) generates news primarily as a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) therapeutics through its proprietary Cloudbreak platform. Most recent coverage focuses on CD388, a long-acting antiviral DFC designed as a non-vaccine preventative for seasonal and pandemic influenza, as well as on corporate transactions and government collaborations.
News about Cidara frequently highlights clinical trial milestones for CD388. This includes updates on the Phase 2b NAVIGATE trial in healthy unvaccinated adults and the Phase 3 ANCHOR trial in adults and adolescents at higher risk of influenza complications, including individuals with immune-compromised conditions, certain comorbidities, and adults over 65 years of age. Articles often describe trial design, enrollment progress, interim analysis plans, and safety and efficacy results reported by the company.
Investors following CDTX news will also see disclosures on regulatory interactions and designations, such as Fast Track and Breakthrough Therapy designations granted by the U.S. Food and Drug Administration (FDA) for CD388, and company commentary on plans to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional coverage includes Cidara’s BARDA agreement to support expanded manufacturing and clinical development of CD388, detailing federal funding for onshoring manufacturing and additional clinical and non-clinical work.
Another major theme in Cidara’s news flow is its acquisition by Merck. Releases describe Merck’s definitive agreement to acquire Cidara through a cash tender offer and subsequent merger, the tender offer terms, and Merck’s statements about integrating CD388 into its respiratory portfolio. Updates from Merck note the successful completion of the tender offer, the planned merger to make Cidara a wholly owned subsidiary, and the expected delisting of Cidara’s common stock from the Nasdaq Global Market.
On this CDTX news page, readers can review historical and transaction-related announcements, clinical data presentations at scientific conferences, investor conference participation, and quarterly corporate updates. For those researching Cidara’s development of CD388, its Cloudbreak platform, and the transition of Cidara into Merck’s portfolio, this news feed provides a centralized view of key public communications over time.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) has appointed Christopher Kurtz as executive vice president of technical operations to advance its antifungal and antiviral programs. With over 26 years of experience, Kurtz's expertise in manufacturing and supply chain management is expected to drive the company's ongoing Phase 3 trials of rezafungin, aimed at treating serious fungal infections. The company also seeks to leverage its Cloudbreak platform for developing long-acting antiviral conjugates against various viruses. The leadership change is viewed as a pivotal step for Cidara's growth and product development.
Cidara Therapeutics (Nasdaq: CDTX) announced its participation in the 7th European Scientific Working Group on Influenza (ESWI) Conference, scheduled for Dec. 6-9, 2020. Highlights include a keynote lecture on the innovative Cloudbreak antiviral platform aimed at universal influenza protection, delivered by Les Tari, Ph.D., on Dec. 7. Additionally, presentations will feature preclinical data on the antiviral conjugate CD377, focusing on its efficacy against various influenza strains, including HPAI and Oseltamivir-resistant isolates. These findings promise advancements in preventing and treating influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced plans to present three posters at the ESICM LIVES 2020 virtual conference from December 6-9, 2020. The presentations will focus on findings from the Phase 2 STRIVE trial of rezafungin for treating candidemia and invasive candidiasis. Key analyses include ICU status, geographic enrollment, and body mass index outcomes compared to caspofungin. Rezafungin is currently undergoing pivotal Phase 3 trials. For further details, copies of the posters will be available on Cidara's website.
Summary not available.
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will participate in two upcoming virtual conferences. The first is the Stifel 2020 Virtual Healthcare Conference, scheduled for November 17, 2020, at 2:00 PM ET. The second event is the 3rd Annual Evercore ISI HealthCONx Conference on December 2, 2020, at 11:20 AM ET, featuring a panel discussion focused on fungal needs. Cidara specializes in developing long-acting therapeutics for fungal and viral infections, including its lead antifungal candidate, rezafungin.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) reported Q3 2020 financial results, highlighting a net loss of $17.6 million, compared to a net income of $3.0 million in Q3 2019. Revenue totaled $2.4 million for the quarter, significantly down from $19.1 million in the same period last year, largely due to a previous intellectual property licensing deal. Research and development expenses increased to $16.3 million, reflecting higher costs related to rezafungin trials. Cidara continues to advance rezafungin through Phase 3, targeting top-line data by late 2021 amid COVID-19 challenges.
Cidara Therapeutics (Nasdaq: CDTX) presented significant clinical data at IDWeek 2020, highlighting its antifungal candidate, rezafungin, for treating candidemia and invasive candidiasis. Analyses from the completed Phase 2 STRIVE trial demonstrated rezafungin's robust efficacy against multiple Candida species across diverse patient populations. Additionally, data on the Cloudbreak antiviral platform showcased the promising antiviral candidate, CD377, which demonstrated strong protective effects against influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced the presentation of two posters at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting, taking place virtually from October 19-30, 2020. The presentations will feature data on rezafungin, a novel once-weekly echinocandin in pivotal Phase 3 trials for treating serious fungal infections. Key presentations include a pharmacoepidemiologic evaluation and results from the Phase 2 STRIVE clinical trial, showcasing consistent trough concentrations across diverse patient populations.
Cidara Therapeutics (Nasdaq: CDTX) will present findings at IDWeek 2020, focusing on rezafungin, a novel once-weekly echinocandin in Phase 3 trials for serious fungal infections. Key presentations include the STRIVE Phase 2 trial results, showcasing consistent trough concentrations and outcomes based on baseline pathogens and BMI. Additionally, new data on CD377, an antiviral candidate against influenza, will be shared. The presentations will occur from Oct. 21-25, 2020, advancing Cidara's mission to enhance treatment standards for fungal and viral infections.
Cidara Therapeutics (Nasdaq: CDTX) announced the participation of Jeffrey Stein, Ph.D., in four upcoming investor conferences in September 2020. Key events include:
- Citi’s 15th Annual BioPharma Conference: September 9, 2020
- H.C. Wainwright 22nd Annual Global Investment Conference: September 14, 2020, at 4:30 PM ET
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 16, 2020, at 3:20 PM ET
- Maxim Conference: September 17, 2020, at 11:00 AM ET
Webcasts available on the company’s website.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
